Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Galena Biopharma Inc (GALE): Should You Buy the Hype Surrounding This Product Launch?

While the analysis of peak sales and potential patient populations may be appealing to most, it costs a great deal of money to launch a new product with success. In the case of Galena Biopharma Inc (NASDAQ:GALE), the company doesn’t have the cash, but touts tremendous sales potential, so might the company succeed anyway?

Galena Biopharma Inc

The reality of launching drugs in healthcare

I would like to share with you something that I think is truly telling about product launches in biotechnology, which are facts surrounding recent product launches.

— Last December, Amarin Corporation plc (ADR) (NASDAQ:AMRN) raised $100 million to assist in the launch of Vascepa. During its most recent quarter, the company spent almost $65 million to aid in Vascepa’s launch. As a result, the company earned $2.34 million in revenue during those initial months. During the last year, shares of Amarin Corporation have declined 60% showing its performance post-approval.

— Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) launched its new drug Iclusig in the first quarter, a drug that treats a form of leukemia. This promising drug, that many believe could achieve annual sales in excess of $1 billion, produced just $6.1 million in its first quarter post-launch. Much like Amarin, the company spent a large deal of money to earn its sales, more than $70 million last quarter.

— VIVUS, Inc. (NASDAQ:VVUS) has had its weight loss product, Qsymia, on the market for the last two quarters. During that period, Vivus has earned just $6 million and has spent more than $115 million. Over the last year, shares of this stock have declined 55%.

The information from these three companies all share certain similarities. Each has products that were once heralded as having billion-dollar potential; many of which still do. All have products that have been expensive to launch and each stock has traded lower during the launch period.

Will this launch be different?

Despite what we see above, Galena Biopharma Inc (NASDAQ:GALE) clearly believes that it will not be “like the others.” The company acquired an FDA approved pain medication called Abstral, which is a form of fentanyl that dissolves under the tongue.

Abstral is already marketed in Europe, but until Galena, no other company had been willing to sell the drug in the U.S. Yet, Galena proudly touts that European marketer ProStrakan reported 2012 sales of $54 million and that Abstral could see peak sales as high as $400 million annually.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.